Pfizer reports positive obesity drug data and beats fourth quarter results
Pfizer reported strong fourth-quarter earnings and promising mid-stage results for its monthly obesity drug. The company plans to expand its clinical program.
Insights:
Pfizer Inc. announced positive mid-stage clinical trial results for its experimental obesity drug PF-3944 and reported fourth-quarter financial results that exceeded analyst expectations. The pharmaceutical giant is positioning these developments as key strategic drivers to mitigate the impact of upcoming patent expirations and provide a foundation for future growth. The company reported that the experimental treatment, acquired through its 10 billion dollar purchase of Metsera last year, showed sustained efficacy in its latest clinical evaluation.
The drug PF-3944, which is administered as a monthly injection, demonstrated sustained weight loss over 28 weeks. In the mid-stage trial, patients without diabetes experienced weight loss of up to 12.3 percent, and Pfizer Inc.noted that no plateau was observed by the 28-week mark. The company stated that it expects this weight-loss trend to continue throughout the duration of the 64-week study. chris boshoff, the head of research and development, is overseeing the advancement of the clinical pipeline as the firm seeks a foothold in the competitive metabolic health sector.
